Oncology Precision Medicine Market, By Component (Therapeutics, Diagnostics / Testing, Informatics & Decision Support, interoperability tools, Services), By Care Pathway Stage (Risk Assessment & Screening, Diagnosis & Tumor Classification, Therapy Selection, Treatment Monitoring, Recurrence Surveillance / MRD, and Clinical Trial Enrolment & Matching, By Technology (Genomics, Transcriptomics, Gene expression profiling / signatures, Proteomics / Protein biomarkers, Mass spectrometry–based proteomics, Cytogenetics & Structural Variation, Single-cell & spatial,Spatial transcriptomics / multiplex imaging), By Biomarker Type (Genetic biomarkers, Genomic signatures / global markers, Tumor mutational burden, Microsatellite instability, Homologous recombination deficiency, Expression / protein markers, Epigenetic biomarkers, MRD biomarkers), By Sample Type (Tissue-based, Blood-based, Whole blood, Other biofluids, Cytology samples), End User (Hospitals & cancer centers, Diagnostic laboratories, Academic & research institutes, Pharmaceutical & biotech companies, CROs / clinical trial networks, and Payers / HTA bodies), By Cancer Type (Solid Tumors, Hematologic Malignancies, and Rare Cancers / Tumor-agnostic Segments), By Reimbursement & Access Channel (Public Reimbursement, Private Reimbursement, Out-of-pocket / Self-pay, Hybrid coverage models, Patient Assistance / Access Programs, and Clinical trial–funded Testing), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)